Biological evaluation of imidazopyridine derivatives as potential anticancer agents against breast cancer cells


SUCU B. O.

Medicinal Chemistry Research, cilt.31, sa.12, ss.2231-2242, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 12
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s00044-022-02984-x
  • Dergi Adı: Medicinal Chemistry Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.2231-2242
  • Anahtar Kelimeler: Imidazo[1, 2-a]pyridine, Anticancer agent, Breast cancer, Suzuki, Acylhydrazone
  • İstanbul Medipol Üniversitesi Adresli: Evet

Özet

Imidazo[1,2-a]pyridine cores have increasing importance in the pharmaceutical industry with their wide range pharmacological activities. In this study, two series of imidazopyridine derivatives were synthesized. It was planned to integrate the pyrimidine ring or N-acylhydrazone (NAH) to the carbon atom at the 3 position of the imidazo[1,2-a]pyridine scaffold. Pyrimidine-containing compounds (9–12) were obtained by palladium-catalyzed coupling reaction (Suzuki reaction), and NAH compounds (13–19) were obtained from the aldehyde intermediate synthesized as a result of the Vilsmeier-Haack reaction. All of the derivatives were evaluated in breast cancer cells for their antiproliferative potential. The pyrimidine-containing compounds did not show active results in both breast cancer cell lines, while the NAH derivatives showed significant results. Among the novel derivatives, compound 15 exhibited the most potent activity against the MCF7 and MDA-MB-231 cell lines with IC50 values of 1.6 and 22.4 μM, respectively. The current study demonstrated that these compounds have anticancer activity and would be useful in developing more effective compounds for treating breast cancer.